Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. (Record no. 24861417)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01937 a2200541 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517031245.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201605s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1573-0646 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/s10637-015-0242-6 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Garcia-Manero, Guillermo |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20160512 |
| 245 00 - TITLE STATEMENT | |
| Title | Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Investigational new drugs |
| Date of publication, distribution, etc. | Aug 2015 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 870-80 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aminopyridines |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aurora Kinases |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Azacitidine |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Hematologic Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Maximum Tolerated Dose |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phenylurea Compounds |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Protein Kinase Inhibitors |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Receptors, Vascular Endothelial Growth Factor |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tibes, Raoul |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kadia, Tapan |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kantarjian, Hagop |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Arellano, Martha |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Knight, Emily A |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Xiong, Hao |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Qin, Qin |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Munasinghe, Wijith |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Roberts-Rapp, Lisa |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ansell, Peter |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Albert, Daniel H |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Oliver, Brian |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | McKee, Mark D |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ricker, Justin L |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Khoury, Hanna Jean |
| 773 0# - HOST ITEM ENTRY | |
| Title | Investigational new drugs |
| Related parts | vol. 33 |
| -- | no. 4 |
| -- | p. 870-80 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1007/s10637-015-0242-6">https://doi.org/10.1007/s10637-015-0242-6</a> |
| Public note | Available from publisher's website |
No items available.